Gastroenteritis  >>  andecaliximab (GS-5745)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
andecaliximab (GS-5745) / Gilead
NCT02405442 / 2015-001249-10: Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease

Terminated
2
187
Canada, US, Europe, RoW
Andecaliximab, GS-5745, Placebo
Gilead Sciences
Crohn's Disease
11/16
12/16

Download Options